Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of “Moderate Buy” by Analysts

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has earned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $43.7143.

CRBP has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, January 21st. Jefferies Financial Group upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 18th. Finally, Oppenheimer boosted their target price on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday.

Corbus Pharmaceuticals Stock Down 1.9%

Shares of Corbus Pharmaceuticals stock opened at $9.41 on Friday. The company’s fifty day simple moving average is $8.30 and its two-hundred day simple moving average is $10.53. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $20.56. The firm has a market cap of $166.93 million, a PE ratio of -1.57 and a beta of 2.84.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.53. As a group, sell-side analysts expect that Corbus Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total value of $26,575.65. Following the sale, the insider owned 95,887 shares in the company, valued at $775,725.83. The trade was a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRBP. Persistent Asset Partners Ltd bought a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $54,000. Virtu Financial LLC purchased a new stake in Corbus Pharmaceuticals in the fourth quarter worth about $88,000. Barclays PLC boosted its position in Corbus Pharmaceuticals by 280.0% during the 4th quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 10,874 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals during the 3rd quarter worth approximately $129,000. Finally, Marshall Wace LLP bought a new position in shares of Corbus Pharmaceuticals in the 2nd quarter worth approximately $137,000. 64.64% of the stock is currently owned by institutional investors.

Trending Headlines about Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $57, signaling strong upside vs. the current share price and providing a bullish catalyst for investors who follow analyst targets. Oppenheimer Boosts Corbus Pharmaceuticals Price Target to $57.00
• Positive Sentiment: The mean of Wall Street analysts’ price targets implies roughly 318% upside, reinforcing the narrative of significant upside potential if clinical or commercial milestones are achieved. This consensus can attract speculative buying and long-term investor interest. How Much Upside is Left in Corbus Pharmaceuticals (CRBP)?
• Neutral Sentiment: Media/analyst roundups (e.g., The Globe and Mail) have included CRBP in broader healthcare coverage, which increases visibility but does not by itself change fundamentals. Investors should watch for any fresh analyst notes contained in these roundups. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Short-interest data published for March shows zero shares and NaN changes — likely a reporting error or an update lag. Because the figures are clearly anomalous, they are not a reliable explanation for price moves unless corrected data appears. (Monitor subsequent short-interest releases.)
• Negative Sentiment: HC Wainwright cut EPS forecasts across multiple quarters and years (Q1–Q4 2026 and FY2026–FY2029/FY2030), lowering near- and medium-term earnings expectations. These downward revisions signal weaker near-term prospects or higher cash burn assumptions and are a clear negative for valuation and investor confidence. What is HC Wainwright’s Estimate for CRBP FY2030 Earnings? MarketBeat HC Wainwright coverage

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.